Liberating Patients Through Cell Therapy
Kyverna (kyvernatx.com) scores 75 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 47th percentile of 19692 Healthcare brands.
Kyverna is a clinical-stage biopharmaceutical company headquartered in Emeryville, United States, that develops CAR T-cell therapies for autoimmune diseases. The company focuses on achieving deep B cell depletion and immune system reset, aiming to provide long-term remission for patients with B cell-driven autoimmune conditions. Kyverna positions itself as patient-centered, applying technology proven in hematological cancers to a new therapeutic area.
| Brand Name | Kyverna |
|---|---|
| Domain | kyvernatx.com |
| Industry | Healthcare |
| Headquarters | Emeryville, United States |
| Main Competitors | Cabaletta Bio (74/100), Cartesian Therapeutics (71/100), Autolus Therapeutics (79/100), Sana Biotechnology (83/100), Poseida Therapeutics (73/100) |
Moz Domain Authority 38/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
Ranked #1,628,929 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Discover Kyverna, a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases." (Meta description: 18 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Nginx, WordPress, Ghost.
Social footprint: verified profiles on X (Twitter), LinkedIn, Instagram, YouTube; no detected presence on Facebook, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Kyverna?", Claude could identify the brand as of October 2026. Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing engineered CAR T-cell therapies to treat severe autoimmune diseases, with its lead candidate KYV-101 being tested in conditions like lupus nephritis and stiff person syndrome. The company went public on Best known for developing KYV-101, an anti-CD19 CAR T-cell therapy for autoimmune diseases.
When asked "Best brands similar to Kyverna?", Claude would recommend Kyverna as of October 2026. It's one of the more notable biotech companies pioneering CAR T-cell therapy specifically for autoimmune conditions rather than cancer, which makes it relevant in discussions of cutting-edge cell therapy approaches.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Kyverna's main competitors in Healthcare: Cabaletta Bio (74/100), Cartesian Therapeutics (71/100), Autolus Therapeutics (79/100), Sana Biotechnology (83/100), Poseida Therapeutics (73/100).
Sources: Brand Analyzer scan
Kyverna has limited AI-search visibility, scoring 34/100 on Brand Analyzer's AI visibility composite (visibility 19, trust 39, recommendation 56). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Kyverna official site
Kyverna scores 56/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Kyverna official site
Kyverna is a clinical-stage biopharmaceutical company based in Emeryville, United States, that develops CAR T-cell therapies specifically designed to treat autoimmune diseases.
Sources: Kyverna official site
Kyverna develops CAR T-cell therapies that achieve deep B cell depletion and immune system reset, aiming to provide long-term remission for patients with B cell-driven autoimmune diseases, building on techniques proven effective in hematological malignancies.
Sources: Kyverna official site
Kyverna can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Kyverna official site
Kyverna offers CAR T-cell therapies designed for autoimmune diseases, leveraging deep B cell depletion and immune system reset mechanisms derived from successful applications in hematological malignancies.
Sources: Kyverna official site
Kyverna is known for pioneering the application of CAR T-cell therapy-originally developed for blood cancers-to the treatment of autoimmune diseases, with a focus on achieving durable remission through B cell depletion and immune system reset.
Sources: Kyverna official site
Kyverna's therapies are intended for patients suffering from autoimmune diseases driven by B cells, and the company engages with the medical and clinical research community involved in treating these conditions.
Sources: Kyverna official site
Kyverna scores 34/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Kyverna has a weak AI-visibility profile at 34/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (56/100) and its weakest is visibility (19/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #1,628,929 (Tranco) and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 38/100 and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Kyverna from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Kyverna: KYON (75/100), Koreatown Youth + Community Center (KYCCLA) (75/100), Labforward (75/100), Labiotech.eu (75/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.